$ANIK News

Bullish On Anika Therapeutics's Pullback As Integrity Scales

Anika Therapeutics Inc (NASDAQ:ANIK) Soars on Q1 Earnings and Revenue Beat

Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript

Anika Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Anika Therapeutics Affirms FY2026 Sales Guidance of $114.000M-$122.500M vs $117.220M Est

Anika Therapeutics Q1 Adj. EPS $0.27 Beats $(0.16) Estimate, Sales $29.612M Beat $28.142M Estimate

Top 2 Health Care Stocks That May Crash This Quarter

Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal Conference - Slideshow

Anika Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

Anika Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Anika Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Insights into Anika Therapeutics Q4 Earnings

Anika Therapeutics Sees FY2026 Sales $114.000M-$122.500M vs $116.351M Est

Anika Therapeutics Q4 Adj. EPS $0.31 Beats $(0.21) Estimate, Sales $30.615M Beat $28.875M Estimate

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors

Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target

Anika Therapeutics Announces Leadership Transition